Olanzapine and Desmethylolanzapine in Serum/Plasma - HPLC

Clinical relevance

Olanzapine and quetiapine are highly effective antipsychotic agents used to treat schizophrenic psychosis. Like clozapine, they are both atypical neuroleptics which are characterised by low levels of side effects in the extrapyramidal motor system (dyskinesia, Parkinson’s disease). Quetiapine is structurally related to olanzapine and is approved as a neuroleptic, but it shows a different receptor profile.

It is essential that the serum levels of these psychotropic drugs be monitored to ensure an optimal therapeutic effect and to minimise any undesirable side effects resulting from overdose. Furthermore, patient compliance gets checked and confirmed by this procedure.

Product advantages

• Low limit of quantification
• Robust UV-VIS detection
• Metabolite analysis included

This assay can be used to reliably determine the levels of olanzapine, its metabolite desmethylolanzapine, and quetiapine in serum or plasma. The sample preparation is based on an efficient and selective solid phase extraction including an internal standard. The chromatographic separation is run on an isocratic HPLC system with UV-VIS detector. When used with additional specific calibrators and controls, perazine and citalopram can also be determined in serum or plasma with this kit.

Our TDM Parameter Set Neuroleptics 1/XT from the MassTox® TDM Series A is available as an alternative for the measurement of these analytes using LC-MS/MS.